Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 53.85 percent increase over losses of $(1.04) per share from the same period last year. The company reported quarterly sales of $13.14 million which beat the analyst consensus estimate of $11.62 million by 13.07 percent. This is a 0.84 percent increase over sales of $13.03 million the same period last year.